UBS Group
DGX icon

UBS Group’s Quest Diagnostics DGX Stock Holding History

UBS Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$1.33M – 9625
2024
Q1 		$1.33M Buy
+10,000
New +$1.3M ﹤0.01% 4352
2021
Q1 		– Sell
-42,822
Closed -$5.1M – 9075
2020
Q4 		$5.1M Buy
+42,822
New +$5.22M ﹤0.01% 2427
2015
Q1 		– Sell
-400
Closed -$27K – 8916
2014
Q4 		$27K Buy
+400
New +$25.2K ﹤0.01% 7219

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

UBS Group's DGX Position: Q2 2026 in Review

UBS Group increased its Quest Diagnostics (DGX) stake by 27% in Q2 2026, buying an estimated $36.6M and bringing the position to 888,906 shares worth $188M. The position accounts for 0.02% of the portfolio, ranked #701.

UBS Group first reported a position in DGX in Q4 2014 and has held it in 47 quarters since. The position peaked at $193M in Q4 2025. 1,109 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • UBS Group held 888,906 shares of Quest Diagnostics worth $188M as of Q2 2026.
  • UBS Group bought 186,569 Quest Diagnostics shares in Q2 2026, an estimated $36.6M.
  • Quest Diagnostics made up 0.02% of UBS Group's portfolio in Q2 2026, its #701 holding.
  • UBS Group first reported a position in Quest Diagnostics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Quest Diagnostics position peaked at $193M in Q4 2025.
  • 1,109 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.